Amyloid plaques are a neuropathologic hallmark of Alzheimerâs disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including11C-Pittsburgh compound B and the18F-labeled compounds such as18F-florbetaben,18F-florbetapir, and18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.
Amyloid PET imaging: Standardization and integration with other Alzheimer's disease biomarkers
Morbelli, Silvia;Bauckneht, Matteo
2018-01-01
Abstract
Amyloid plaques are a neuropathologic hallmark of Alzheimerâs disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including11C-Pittsburgh compound B and the18F-labeled compounds such as18F-florbetaben,18F-florbetapir, and18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.
| File | Dimensione | Formato | |
|---|---|---|---|
|
morbelli2018.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
284.06 kB
Formato
Adobe PDF
|
284.06 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
